3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hematologic Neoplasms
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Liver Neoplasms
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
Docetaxel
7
pembrolizumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Cisplatin
3
Vorinostat
2
Taxes
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Gene Expression Profiling
2
Filgrastim
2
Cetuximab
2
Biopsy
2
zanidatamab
1
vandetanib
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
talactoferrin alfa
1
spartalizumab
1
sargramostim
1
pertuzumab
1
neratinib
1
larotrectinib
1
fluoromisonidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
pertuzumab
×
Thoracic
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled